07:00 , Apr 4, 2016 |  BC Week In Review  |  Company News

Orexo, AstraZeneca deal

AstraZeneca exercised a 2013 option to license exclusive, worldwide rights to Orexo’s OX-CLI program. The leukotriene C4 synthase (LTC4S) inhibitor is in preclinical development to treat respiratory disorders, including asthma and chronic obstructive...
08:00 , Jan 28, 2013 |  BC Week In Review  |  Company News

Orexo, AstraZeneca deal

Orexo granted AstraZeneca rights to conduct further preclinical research of compounds in Orexo's OX-CLI program, which comprises compounds that inhibit leukotriene C4 synthase (LTC4S) in preclinical development for respiratory diseases. The pharma also...
08:00 , Jan 28, 2013 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) lost $2.74 to $94.68 last week after announcing the U.K. Ministers of Health deferred a decision to cover Soliris eculizumab on the NHS for atypical hemolytic uremic syndrome (aHUS). According...
02:37 , Jan 26, 2013 |  BC Extra  |  Company News

AstraZeneca gets option to preclinical Orexo program

Orexo AB (SSE:ORX) granted AstraZeneca plc (LSE:AZN; NYSE:AZN) rights to conduct further preclinical research of compounds in Orexo's OX-CLI program, which comprises compounds that inhibit leukotriene C4 synthase (LTC4S) in preclinical development for respiratory diseases....
07:00 , Mar 29, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Dermatology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Dermatology Dermatitis Cysteinyl leukotriene receptor 2 (CYSLTR2; CysLT2); leukotriene C4 synthase (LTC4S) Mouse...
08:00 , Feb 6, 2012 |  BC Week In Review  |  Company News

Orexo, J&J deal

Orexo and Johnson & Johnson's Janssen Pharmaceuticals Inc. (formerly Ortho-McNeil-Janssen Pharmaceuticals Inc.) and Janssen Pharmaceutica N.V. subsidiaries, mutually terminated a 2010 deal granting the subsidiaries exclusive, worldwide rights to develop and commercialize Orexo's OX-CLI...
07:00 , May 5, 2011 |  BC Innovations  |  Cover Story

LIGHTs out for asthma

Two years after Kyowa Hakko Kirin Co. Ltd.granted sanofi-aventis Groupan exclusive license to an antibody against the tumor necrosis factor ligand LIGHT to treat irritable bowel disease, researchers at the La Jolla Institute for Allergy...
07:00 , Jun 7, 2010 |  BC Week In Review  |  Company News

Orexo, J&J deal

Johnson & Johnson's Ortho-McNeil-Janssen Pharmaceuticals Inc. and Janssen Pharmaceutica N.V. subsidiaries received worldwide, exclusive rights to develop and commercialize OX-CLI and OX-ESI. The compounds, which inhibit leukotriene C4 synthase (LTC4S) and arachidonate...
07:00 , Jun 7, 2010 |  BioCentury  |  Strategy

J&J's Pulmonary Push

In a pair of deals last week, Johnson & Johnson doubled the number of compounds in its disclosed pipeline for respiratory diseases from four to eight, and it sounds like the pharma is still shopping. J&J's...
01:11 , Jun 2, 2010 |  BC Extra  |  Company News

J&J units in pulmonary deals

Three Johnson & Johnson (NYSE:JNJ) units announced pulmonary and respiratory deals on Tuesday, including a licensing deal with Orexo AB (SSE:ORX) and the acquisition of RespiVert Ltd. (London, U.K.). J&J's Centocor Ortho Biotech Inc. unit...